Início › Neoplasias Mieloproliferativas › Texas › Houston
Ensaios clínicos de Neoplasias Mieloproliferativas em Houston, TX
16 estudos para Neoplasias Mieloproliferativas estão buscando participantes em locais em Houston e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecrutandoFase 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecrutandoEstudo observacional
- Texas Children's Hospital, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecrutandoFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecrutandoFase 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RecrutandoFase 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecrutandoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RecrutandoFase 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RecrutandoFase 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
RecrutandoEstudo observacional
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecrutandoFase 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
RecrutandoFase 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RecrutandoFase 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RecrutandoFase 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecrutandoFase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
RecrutandoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Ensaios de Neoplasias Mieloproliferativas em outras cidades
- New York City, NY15 estudos
- Boston, MA14 estudos
- Milwaukee, WI10 estudos
- Miami, FL10 estudos
- Chicago, IL9 estudos
- Durham, NC9 estudos
- Baldwin Park, CA9 estudos
- Seattle, WA9 estudos
- Atlanta, GA8 estudos
- Tampa, FL8 estudos
- Birmingham, AL8 estudos
- Columbus, OH8 estudos
Outros estudos em Houston
- Câncer de Pulmão de Não Pequenas Células145 estudos
- Câncer de Mama126 estudos
- Câncer (todos os tipos)121 estudos
- Câncer Metastático104 estudos
- Câncer Colorretal102 estudos
- Câncer de Ovário89 estudos
- Leucemia Mieloide Aguda85 estudos
- Câncer de Pulmão78 estudos
- Câncer de Próstata76 estudos
- Câncer Endometrial68 estudos
- Câncer de Pâncreas61 estudos
- Melanoma59 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.